Strategic Partnership

Helmholtz Zentrum München and Novo Nordisk extended their research collaboration in metabolic diseases

Helmholtz Zentrum München and Novo Nordisk recently extended their multi-year strategic partnership which aims to identify and jointly develop novel targets and enabling technologies, ultimately supporting the development of innovative medicines for metabolic diseases.


The collaboration leverages the scientific knowledge, expertise and translational research capabilities of Helmholtz Zentrum München researchers and Novo Nordisk’s extensive know-how within research, clinical development and commercialization of pharmaceutical products against chronic metabolic diseases.